BiotechTube

Radiprodil

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infantile Spasms (IS)

Conditions

Infantile Spasms (IS)

Trial Timeline

Dec 4, 2017 → Oct 2, 2018

NCT ID
NCT02829827

About Radiprodil

Radiprodil is a phase 2 stage product being developed by UCB for Infantile Spasms (IS). The current trial status is terminated. This product is registered under clinical trial identifier NCT02829827. Target conditions include Infantile Spasms (IS).

What happened to similar drugs?

3 of 7 similar drugs in Infantile Spasms (IS) were approved

Approved (3) Terminated (2) Active (4)
✅alglucosidase alfa + alglucosidase alfaSanofiApproved
✅Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
✅VigabatrinLundbeckApproved
🔄GWP42003-PJazz PharmaceuticalsPhase 3
🔄GWP42003-PJazz PharmaceuticalsPhase 3
🔄Cholic AcidsMirum PharmaceuticalsPhase 3
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02829827Phase 2Terminated

Competing Products

16 competing products in Infantile Spasms (IS)

See all competitors
ProductCompanyStageHype Score
TSHA-101Taysha Gene TherapiesPhase 1/2
30
MAS825 + PlaceboNovartisPhase 2
39
alglucosidase alfa + alglucosidase alfaSanofiApproved
35
MyozymeSanofiPhase 2
35
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
43
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
23
Sabril®LundbeckPre-clinical
23
VigabatrinLundbeckApproved
32
NusinersenBiogenPre-clinical
23
GWP42003-PJazz PharmaceuticalsPhase 3
37
GWP42003-PJazz PharmaceuticalsPhase 3
37
Cerliponase AlfaBioMarin PharmaceuticalPre-clinical
27
Cholic AcidsMirum PharmaceuticalsPhase 3
37
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
ATB200 + AT2221Amicus TherapeuticsPre-clinical
27
RP-L401Rocket PharmaceuticalsPhase 1
11